Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Synthekine
Biotech
Synthekine hopes new IL-2 will be the high-alpha in a beta class
IL-2 medicines have shown the ability to kill tumors. Synthekine hopes to do this without the associated toxicities with a new IL-2 alpha/beta molecule.
Annalee Armstrong
Apr 10, 2024 9:50am
AbbVie names CEO successor—Chutes & Ladders
Feb 23, 2024 9:30am
Sanofi pays $40M to join preclinical push against vexing target
Jan 29, 2024 8:00am
Fierce Biotech's 2022 Fierce 15
Sep 12, 2022 3:00am
Merck inks $525M biobucks pact for Synthekine's cytokine target
Nov 1, 2021 8:00am
Asher Bio snags $108M series B for three immunotherapy programs
Sep 1, 2021 7:00am